2 days ago
Aurobindo Pharma shares in focus after European Commission nod for cancer drug Dazublys
Synopsis
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, secured European Commission approval for its trastuzumab biosimilar, Dazublys, indicated for HER2-positive cancers. This marks CuraTeQ's third EMA-approved biosimilar in 2025, reinforcing Aurobindo's focus on biosimilars with plans for 10 launches by 2030. Analysts predict a potential 20% upside for Aurobindo Pharma shares, with a consensus 'Buy' rating.
